Acral erythema in children receiving high-dose methotrexate.
Scant information is available concerning the occurrence and evolution of chemotherapy-induced acral erythema in children receiving intravenous high-dose methotrexate (MTX). Among 50 children with acute lymphoblastic leukemia or lymphoblastic lymphoma receiving a total of 203 courses of high-dose MTX (3-8 g/m2), 3 cases of acral erythema were observed. Painful erythema of finger and toe pads was noted in three children 3 days to 2 weeks after MTX infusion. The lesions resolved completely after blister formation and desquamation. These patients subsequently received high-dose MTX therapy without cutaneous problems. The present work points out that the chemotherapeutic schedule need not be modified in selected patients who develop acral erythema following high-dose MTX infusion.
Millot
F
F
Department of Hematology, University Hospital of Poitiers, France. f.millot@chu.univ-poitiers.fr
Auriol
F
F
Brecheteau
P
P
Guilhot
F
F
D000293:Adolescent; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage / Q000009:adverse effects*; D002051:Burkitt Lymphoma / Q000188:drug therapy; D002648:Child; D004305:Dose-Response Relationship, Drug; D004890:Erythema / Q000139:chemically induced* / Q000175:diagnosis; D005260:Female; D006229:Hand Dermatoses / Q000139:chemically induced* / Q000175:diagnosis; D006801:Humans; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage / Q000009:adverse effects*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy
D000964:Antimetabolites, Antineoplastic; D008727:Methotrexate